Inflammatory bowel disease (IBD) is a chronic inflammatory condition associated with disability and reduced quality of life.1 Corticosteroids temporarily treat inflammation, but guidelines recommend against their long-term use because of their toxicity profile and ineffectiveness at maintaining clinical remission (the resolution of symptoms).2,3 Patients with moderate to severe IBD are often prescribed corticosteroid-sparing therapies, such as anti–tumor necrosis factor (TNF) agents, for the induction and maintenance of clinical remission. Here, TNF is linked to inflammatory bowel disease.